The underlying mechanism of DMAMCL’s efficacy in these cancers is likely associated with its induction of Bim, modulation of the NF-κB pathway, ROS generation in RMS cell lines, and reduction of osteosarcoma stem cell stemness (Ba et al., 2020; Xu et al., 2019). The gene discussed is NFKB1; the disease is cancer.